Vicky E. Macrae

IGF-I signalling in bone growth: inhibitory actions of dexamethasone and IL-1beta.

Inhibition of PHOSPHO1 activity results in impaired skeletal mineralization during limb development of the chick.

The importance of the SIBLING family of proteins on skeletal mineralisation and bone remodelling.

Pharmacological inhibition of PHOSPHO1 suppresses vascular smooth muscle cell calcification.

Mechanisms and clinical consequences of vascular calcification.

A protective role for FGF-23 in local defence against disrupted arterial wall integrity?

Upregulation of IGF2 expression during vascular calcification.

Optimisation of the differing conditions required for bone formation in vitro by primary osteoblasts from mice and rats.

Mineralisation of collagen rich soft tissues and osteocyte lacunae in Enpp1(-/-) mice.

Deficiency of the bone mineralization inhibitor NPP1 protects against obesity and diabetes.

Increased linear bone growth by GH in the absence of SOCS2 is independent of IGF-1.

Effects of etidronate on the Enpp1⁻/⁻ mouse model of generalized arterial calcification of infancy.

New perspectives on rare connective tissue calcifying diseases.

Editorial overview: Musculoskeletal: Where are we with treating musculoskeletal disorders?

Ablation of the androgen receptor from vascular smooth muscle cells demonstrates a role for testosterone in vascular calcification.

A novel role for the mineralocorticoid receptor in glucocorticoid driven vascular calcification.